The DOI matches its Crossref record, with a small difference in title or year; 100 of the 102 references it cites were found in a registry or an index.
Investigation, treatment and monitoring of late-onset hypogonadism in males
Open accessAbstract
Demographic data clearly demonstrate that the percentage of the population in the older age group is increasing. Androgen deficiency in the aging male has become a topic of increasing interest and debate throughout the world. Cross-sectional and longitudinal data indicate that the testosterone falls progressively with age and that a significant percentage of men over the age of 60 years have serum testosterone levels that are below the lower limits of young adult (age 20–30 years) men (1, 2, 3, 4). The principal questions raised by these observations are whether older hypogonadal men will benefit from testosterone treatment and what will be the risks associated with such intervention. The past decade has brought evidence of benefit of androgen treatment of hypogonadal men on multiple target organs and the recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men. This has been comprehensively reviewed and summarized by the Institute of Medicine in ‘Testosterone and Aging: Clinical Research Directions’ (5). Long-term data on the effects of testosterone treatment in the older population are limited mainly to effects on body composition and bone mass (6, 7, 8, 9, 10, 11). Key questions of the effects of testosterone on patient reported outcomes and functional benefits that may retard physical or mental frailty of the elderly or improve the quality of life are not yet available. Specific risk data on the prostate and cardiovascular systems are needed. Recent guidelines for the testosterone treatment of younger hypogonadal men are available from professional societies (12, 13, 14). Recommendations on the diagnosis, treatment, and monitoring of late-onset hypogonadism (LOH) were published by International Society for the Study of Aging Male (ISSAM) in 2002 (15). In 2005, a writing committee formed by the International Society of Andrology (ISA), the ISSAM, and the European Association of Urology (EAU) prepared a set of recommendations specifically on the ‘Investigation, treatment and monitoring of LOH’. In order to reach a large audience, these recommendations were published in the International Journal of Andrology, the Journal of Andrology, the Aging Male, and European Urology (16, 17, 18, 19). In view of the growing interest from practitioners on the treatment of older men with testosterone, the ISA, ISSAM, EAU, European Academy of Andrology, and American Society of Andrology convened meetings of the writing group with expert representatives from each of the societies. The writing group membership from 2005 was expanded to include additional urologists. Members of the writing group met in Berlin 2007, Toronto 2007, and Tampa 2008 to revise these recommendations. There was no corporate funding or support for the development of these recommendations. The revised recommendations are supported by a selection of appropriate references and categorized by the level of evidence and grade of recommendation according to the US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research (1992; Table 1). Level of evidence and grade of recommendation utilized in the recommendations. Level of evidence and grade of recommendation utilized in the recommendations. To ensure broad outreach to multidisciplinary audiences, these recommendations are published in several journals simultaneously. LOH, also referred to as age-associated testosterone-deficiency syndrome (TDS), is a clinical and biochemical syndrome associated with advancing age and characterized by symptoms and a deficiency in serum testosterone levels (below the young healthy adult male reference range) (16, 17, 18, 19, 20). This condition may result in significant detriment in the quality of life and adversely affect the function of multiple organ systems. 2.1. At present, the diagnosis of treatable hypogonadism requires the presence of symptoms and signs suggestive of testosterone deficiency (Level 3, Grade A) (12, 16, 17, 18, 19). The symptom most associated with hypogonadism is low libido (Level 3, Grade A) (21, 22). Other manifestations of hypogonadism include: erectile dysfunction, decreased muscle mass and strength, increased body fat, decreased bone mineral density and osteoporosis, and decreased vitality and depressed mood. None of these symptoms are specific to the low androgen state but may raise suspicion of testosterone deficiency. One or more of these symptoms must be corroborated with a low serum testosterone level (Level 3, Grade A) (1, 23, 24, 25). 2.2. Questionnaires such as Aging Male Symptom Score (AMS) (26, 27) and Androgen Deficiency in Aging Men (ADAM) (28) are not recommended for the diagnosis of hypogonadism because of low specificity (Level 3, Grade B) (24, 29, 30). 3.1. In patients at risk or suspected of hypogonadism, a thorough physical and biochemical work-up is necessary (Level 4, Grade A). Transient decreases of serum testostero
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other studies have also demonstrated increased associations between fT and other comorbid conditions, including depression and hypogonadal symptoms.”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [97]
In the citing paper
“There is a degree of consensus that elderly men with serum testosterone clearly below the reference ranges and persistent clear clinical signs of hypogonadism may justifiably be treated (98, 99)”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Self-citationJOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
Hoskins, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
The Practice Committee of the American Society for Reproductive Medicine
Birmingham, A. (2006) · Cited by 1,925
Journal of the American Geriatrics Society
(1976) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1976.tb03307.x · Cited by 1,309
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176
Gray, A., Feldman, H. A., McKinlay, J. B., & Longcope, C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1016 · Cited by 1,104
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationAssessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chen, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 941
Self-citationWu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939
Self-citation
Research works printed but not linked: 2
- McConnell JD Prostatic growth: new insights into hormonal regulation British Journal of Urology 76 Suppl 1 1995 5 10 7544215
- Nieschlag E Behre HM Testosterone: Acion, Deficiency, Substitution edn. 3. 2004 Cambridge University Press Cambridge
Cited by
Sorted by citations
Items 801–868 of 868
Hipogonadismo: nueva propuesta de clasificación basada en el mecanismo inductor
Arcila, J. F. U. (2014) · Revista Urología Colombiana / Colombian Urology Journal · doi:10.1016/s0120-789x(14)50038-x
Preoperative hormonal pattern in patients undergoing radical prostatectomy due to prostate cancer
García-Cruz, E., Castañeda-Argáiz, R., Carrión, A., Alcover, J., Sallent, A., Leibar-Tamayo, A., Romero-Otero, J., & Alcaraz, A. (2013) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2013.09.001
Treatment of Erectile Dysfunction in the Older Diabetic Patient
Sukumar, N., & Basu, A. (2010) · Aging Health · doi:10.2217/ahe.09.82
Farrell, J. A. B., Deshmukh, A., & Baghaie, A. A. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.59
Diagnóstico e Tratamento do Hipogonadismo Masculino Tardio
Alves, M., Neves, C., & Medina, J. L. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Testosterone and Its Association with Metabolic and Cardiovascular Disease
Corona, G., Rastrelli, G., & Maggi, M. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-179-0_5
Treatment for late-onset hypogonadism: the current situation in Japan
Tsujimura, A., & Okuyama, Ä. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.10.003
Testosterone and frailty in elderly men
Emmelot‐Vonk, M. H. (2009) · Utrecht University Repository (Utrecht University)
Gutiérrez-Hernández, P. R., & Rebollo, P. (2013) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2013.11.001
Trzmiel, A., Filus, A., Kuliczkowska-Płaksej, J., & Therapy, I. (2009)
Low Testosterone Levels in Male Patients with Hypertension,
Agarwal, S. K. (2015)
Júnior, A. D. S., Clapauch, R., & Buksman, S. (2009)
Tishova, Y. A., & Kalinchenko, S. Y. (2009)
Il ruolo del testosterone e dell’estradiolo nell’età avanzata
Tozzoli, R., & Fortunato, A. (2011) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.1007/s13631-011-0015-y
García-Cruz, E., Gosálbez, D., Sallent, A., Piqueras, M., Leibar-Tamayo, A., Otero, J., Castañeda-Argáiz, R., Carrión, A., Asiaín, I., Arrom, L. M., et al. (2014) · Journal of Men s Health · doi:10.1089/jomh.2014.0021
Phongkitkarun, S., Rassameepong, A., Permpongkosol, S., Taphey, M., & Wibulpolprasert, B. (2012) · PubMed
The Clinical relevance of serum testosterone and sexual activity in the ageing male
Journals, I., Diya, K., & Bayumi, E. K. (2015) · Figshare · doi:10.6084/m9.figshare.1524128
Eskelinen, S. I. (2008) · UTUPub (University of Turku)
Ist es „nur“ das Alter oder braucht er Testosteron?
Heufelder, A. E., Wetterauer, U., & Yassin, A. A. (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-3642-1
Review Article Andropause: Current concepts
Singh, P. (2013)
Hipogonadismo de inicio tardío: Un síndrome prevalente pero poco detectado
Marcelo Marconi, T., Erika Petricevic, O., & Daniela Fleck, L. (2012)
Benefits of testosterone replacementHACKETT
Hackett, G. I. (2013)
Testosterone replacement therapy
Vrolyk, M. (2015) · OpenBU (Boston University)
[Clinical and biochemical diagnosis of androgenic deficit in adult men].
Mas, M. (2013) · PubMed
Antonini, G., Di, A. K., De, E., Radicioni, F., & Vanacore, N. (2011)
Endocrinological investigation of men with erectile dysfunction
Corona, G., Vignozzi, L., & Maggi, M. (2016) · doi:10.1002/9781118746509.ch10
Causas y consecuencias del hipogonadismo en varones con diabetes mellitus tipo 2
Ruiz, A. H. (2015) · Gredos (University of Salamanca) · doi:10.14201/gredos.128430
Clinical Manifestation and Diagnosis of Androgen Deficiency
Święcicka, A., & Wu, F. C. W. (2017) · Endocrinology · doi:10.1007/978-3-319-29456-8_23-1
Self-citationBasic Principles of the Princeton Recommendations
Whelan, P. S., & Nehra, A. X. (2014) · Springer eBooks · doi:10.1007/978-3-319-08272-1_22
Fui, M. N. T., & Mark, A. (2017) · Minerva Access (University of Melbourne)
Comment je prescris un traitement substitutif pour hypogonadisme
Rébibo, J. D. (2018) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2018.03.002
Hipogonadismo associado à obesidade: efeitos do tratamento com citrato de clomifeno
Soares, A. H. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-13062018-074535
Testosterone Therapy: Do American and European Clinicians Have Different Approaches?
Trost, L. W., & Zitzmann, M. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.07.010
Estrogen for Male Function: Effect of Changes in the Sex Hormone Milieu on Erectile Function
Kataoka, T., & Kimura, K. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81162
Treatment of Adult Male Hormonal Disorders
Clavijo, R. I. (2020) · Springer eBooks · doi:10.1007/978-3-030-28599-9_22
HORMONAL AND CLINICAL PROFILE OF HYPOGONADISM IN DIABETES PATIENTS
Hambhire, D. (2019) · International Journal of Medical and Biomedical Studies · doi:10.32553/ijmbs.v3i6.774
Park, S., Cho, S., Kim, J. Y., Yeo, J. K., & Park, M. S. (2020) · Journal of Men s Health · doi:10.15586/jomh.v16isp1.248
Лебедева, Н. Б., Gofman, V. V., Melnikova, V. A., Dymova, O. I., & Ustyuzhanina, O. F. (2020) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2020-98-2-130-136
Understanding the Controversy Regarding Treatment of Age-Related Testosterone Deficiency
Morgentaler, A. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0006
The Prevalence of Late-Onset Hypogonadism in Middle-Aged Men and Cardiovascular Risk Factors
Lebedeva, N. B., & Gofman, V. V. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0020
Kaufman, J. (2022) · doi:10.1093/med/9780198870197.003.0483
Self-citationLittle, M. O., & Morley, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.02.009
Self-citationBehre, H. M., & Nieschlag, E. (2011) · doi:10.1093/med/9780199235292.003.9037
Self-citationMultifaktorielle „Männerkrankheiten“
Diederich, S. (2012) · Medizinisch Wissenschaftliche Verlagsgesellschaft eBooks · doi:10.32745/9783954660162-2.14
(2013) · Andrologie · doi:10.1007/12610.1760-5377
Husain, A. A., Abdel-Raheum, M., Barsoum, N. M., & El-Sattar, A. (2019) · Minia Journal of Medical Research · doi:10.21608/mjmr.2022.221742
Marhenke, T. (2020) · Essentials · doi:10.1007/978-3-658-32169-7_2
Treatment of hypogonadism and infertility
Nieschlag, E. (2011) · doi:10.1093/med/9780199235292.003.9104
Self-citationMissbrauch von Anabolen Androgenen Steroiden (AAS)
Vorona, E., & Nieschlag, E. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-61904-9_37-1
Self-citationMissbrauch von Anabolen Androgenen Steroiden (AAS)
Vorona, E., & Nieschlag, E. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61901-8_37
Self-citationYang, H., Winnegrad, Z., Obiora, D., & Seftel, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-77575-5.00030-7
Filho, T. R. C., de Jesus, M. L., Braga, V. S., Siqueira, T. L., & Amaral, A. L. D. A. (2023) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2023v5n4p2595-2606
Yangjing Capsule Increases Testosterone Production through SET/PI3K/Akt Pathway in Leydig Cell
Xing, D., Liu, Y., Sun, D., Wang, D., Jin, Y., Cai, B., & Jin, B. (2023) · Andrologia · doi:10.1155/2023/4144490
Abuse of Anabolic Androgenic Steroids (AAS) for Doping
Vorona, E., & Nieschlag, E. (2023) · Springer eBooks · doi:10.1007/978-3-031-31574-9_37 · Cited by 1
Self-citationObesity associated hypogonadism—a growing concern in metabolic syndrome
Majumdar, S., Jacob, J. J., & Jude, E. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00054-2 · Cited by 1
Hsf1/Hsp25 System Protects Mitochondria Function and Maintains Star Synthesis in Ma-10 Leydig CellsPreprint
Oka, S., Takii, R., Fujimoto, M., Nakai, A., & Shiraishi, K. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4865072
Neuzillet, Y., Raynaud, J., Dreyfus, J., Radulescu, C., Rouanne, M., Schneider, M., Krish, S., Morgan Rouprêt, A., Drouin, S., Compérat, É., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.08.003
Vincentis, S. D., David, K., Antonio, L., & Rochira, V. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_22
Testosterone Deficiency Syndrome
Meryn, S. (2014) · Springer eBooks · doi:10.1007/978-3-662-45018-5_10
Management of Primary Hypogonadism in Men with NOA
Böcü, K., & Gül, M. (2026) · Springer eBooks · doi:10.1007/978-3-031-99431-9_6
The Aging Male Endocrine System: Clinical Insights into Andropause Management
Garg, R. (2026) · Journal of The Indian Academy of Geriatrics · doi:10.4103/jiag.jiag_83_25
Hypogonadism and Metabolic Disorders
Cignarelli, A., Genchi, V. A., & Jayasena, C. N. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_50-1
Diagnosis and Treatment of Andropause
Özenç, G., & İMAMOĞLU, M. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-28741-0_12
The Use of Patient Reported Outcome Questionnaires in the Diagnosis of Androgen Deficiency
Lowe, G. J., Bailey, G. C., & Krupski, T. L. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-179-0_4
Ipogonadismo tardivo dell’adulto: inquadramento diagnostico
Foresta, C., & Mambro, A. D. (2010) · L Endocrinologo · doi:10.1007/bf03344711
Hypogonadism and metabolic syndrome.
(2011) · PubMed · doi:10.3275/7806 · Cited by 125
Metadata
- Authors
- Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., Morley, J. E., Schulman, C., Thompson, I. M., Weidner, W., & Wu, F. C. W.
- Affiliations
- University of California, Los Angeles (US)
- University of Münster (DE)
- University Hospital in Halle (DE)
- Tulane University (US)
- Vrije Universiteit Amsterdam (NL)
- Ghent University Hospital (BE)
- University of Liège (BE)
- Bar-Ilan University (IL)
- St. Louis VA Medical Center (US)
- Université Libre de Bruxelles (BE)
- The University of Texas at San Antonio Health Science Center (US)
- Justus-Liebig-Universität Gießen (DE)
- Manchester Royal Infirmary (GB)
- Corresponding author
- Wang, C
- ORCID
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-11
- Volume
- 159
- Issue
- 5
- Pages
- 507-514
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- PMC
- PMC2754376
- OpenAlex
- W2097830439
- Cited by
- 867
- References
- 102
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 13 · 2023: 15 · 2022: 24 · 2021: 25 · 2020: 31 · 2019: 33 · 2018: 22 · 2017: 39 · 2016: 43 · 2015: 58 · 2014: 88 · 2013: 89 · 2012: 106
- FWCI
- 60.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Journal of Endocrinology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- andropause, male hypogonadism, testosterone replacement therapy, older men, androgen deficiency, prostate cancer risk, cardiovascular risk, treatment monitoring, quality of life, frailty, body composition, bone mass, European Association of Urology
- MeSH terms
- Aging, Endocrinology, Europe, Humans, Hypogonadism, Male, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
